help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berezin, M.
Right arrow Articles by Lunenfeld, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berezin, M.
Right arrow Articles by Lunenfeld, B.

Journal of Clinical Endocrinology & Metabolism, Vol 59, 1220-1223, Copyright © 1984 by Endocrine Society

ARTICLES

Reduction of follicle-stimulating hormone (FSH) secretion in FSH- producing pituitary adenoma by bromocriptine

M Berezin, D Olchovsky, A Pines, R Tadmor and B Lunenfeld

An FSH-secreting pituitary adenoma was demonstrated in a 32-yr-old man who presented with unilateral optic atrophy without any clinical or laboratory evidence of hypogonadism. Semen analysis was normal, although basal FSH levels were markedly elevated (greater than 80 mIU/ml). He had normal plasma LH levels and no other detectable endocrine abnormalities. Administration of GnRH elicited delayed and sustained FSH and brisk LH responses. Administration of TRH resulted in TSH and PRL responses and unexpected FSH and LH elevations. Two surgical operations resulted in temporary reduction of plasma FSH levels, but it increased later concomitant with CT demonstration of tumor growth. After pituitary irradiation, no reduction in FSH levels occurred. A single dose of 5 mg bromocriptine elicited a significant reduction in FSH levels from 137 to 64 mIU/ml. Long term treatment with 15 mg/day bromocriptine resulted in further reduction of FSH level, to 36.4 mIU/ml, without any change in tumor size. This finding implies that bromocriptine could be an adjunctive therapy or an alternative to other modes of treatment in patients with these rare tumors.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
Y. Murata, H. Ando, T. Nagasaka, I. Takahashi, K. Saito, H. Fukugaki, K. Matsuzawa, and S. Mizutani
Successful Pregnancy after Bromocriptine Therapy in an Anovulatory Woman Complicated with Ovarian Hyperstimulation Caused by Follicle-Stimulating Hormone-Producing Plurihormonal Pituitary Microadenoma
J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1988 - 1993.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
I. Shimon, T. Rubinek, I. Bar-Hava, D. Nass, M. Hadani, A. Amsterdam, and G. Harel
Ovarian Hyperstimulation without Elevated Serum Estradiol Associated with Pure Follicle-Stimulating Hormone-Secreting Pituitary Adenoma
J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3635 - 3640.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1984 by The Endocrine Society